Kyverna Therapeutics, Inc. KYTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $30.07M-19.7% | $30.01M-10.4% | $30.46M+4.3% | $35.82M+31.1% | $37.43M+66.5% | ||
| $11.29M+13.2% | $9.27M+22.6% | $8.27M-13.6% | $8.59M+40.6% | $9.98M+44.9% | ||
| $41.37M-12.7% | $39.28M-4.3% | $38.73M-0.1% | $44.41M+32.8% | $47.41M+61.5% | ||
| -$41.37M+12.7% | -$39.28M+4.3% | -$38.73M+0.1% | -$44.41M-32.8% | -$47.41M-61.5% | ||
| $667K+2,568% | $444K+1,544% | $7K-78.1% | $14K-64.1% | $25K-43.2% | ||
| $1.64M-40.9% | $1.48M-58.4% | $1.94M-54.7% | $2.33M-49.7% | $2.77M+4.1% | ||
| -$39.73M+11.0% | -$37.8M-0.8% | -$36.79M-6.7% | -$42.08M-46.1% | -$44.64M-67.2% | ||
| -$0.66+35.9% | -$0.79+10.2% | -$0.85-6.2% | -$0.97-44.8% | -$1.03+8.0% | ||
| -$41.02M+12.6% | -$38.91M+3.9% | -$38.31M-0.3% | -$43.9M-33.4% | -$46.91M-62.4% | ||
| -$41.37M+12.7% | -$39.28M+4.3% | -$38.73M+0.1% | -$44.41M-32.8% | -$47.41M-61.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Kyverna Therapeutics, Inc. profitable?
- Kyverna Therapeutics, Inc. is not currently profitable: it reported a net loss of $156.4M over the trailing twelve months.
- What is Kyverna Therapeutics, Inc.'s earnings per share?
- Kyverna Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.27.
- Where does Kyverna Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.